
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+3
Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricors innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product...
Biotechnology,duchenne muscular dystrophy,rna therapeutics,extracellular vesicles ,exosomes,cell therapy ,rare diseases,and infectious diseases
Capricor therapeutics, inc operates in the Biotechnology research industry.
Capricor therapeutics, inc's revenue is 11m - 100m
Capricor therapeutics, inc has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.